- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02877706
French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia (CARMEN)
July 27, 2023 updated by: University Hospital, Toulouse
CARMEN is a national, real-world clinical registry of all adult patients with incident diagnosis of Immune thrombocytopenia (ITP) or Autoimmune Hemolytic anemia (AIHA) patients in France.
It is aimed at describing ITP and AIHA clinical features, assessing the real-world risk-benefit ratio of treatments and adherence to guidelines for ITP and AIHA management.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
1500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Moulis Guillaume, MD PhD
- Email: moulis.g@chu-toulouse.fr
Study Contact Backup
- Name: Johanne Germain, PhD
- Email: johanne.germain@inserm.fr
Study Locations
-
-
-
Toulouse, France, 31000
- Recruiting
- Service de Médecine Interne
-
Contact:
- Moulis Guillaume, MD, PhD
- Email: moulis.g@chu-toulouse.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Multicentric adult ITP and AIHA case recording in France, selected in centers of the French Referral Autoimmune Cytopenia Network.
Both secondary and tertiary (referral) centers are participating (N=44).
Description
Inclusion Criteria:
- adult patients (18+ year-old)
- newly diagnosed for ITP/AIHA or initiation of FOSFAMATINIB
Exclusion criteria:
- opposition to data collection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Immune thrombocytopenia (ITP) and AIHA
Time Frame: Baseline
|
Number of new cases
|
Baseline
|
Natural evolution and events
Time Frame: Baseline and follow-up
|
Disease duration.
Description of bleeding, infection, thrombosis events
|
Baseline and follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response
Time Frame: 15 years
|
platelet count >30 G/L and no bleeding
|
15 years
|
Complete rate
Time Frame: 15 years
|
platelet count >30 G/L and no bleeding
|
15 years
|
Treatment lines
Time Frame: 15 years
|
% of patients with each treatment by line of treatments
|
15 years
|
Adverse drug reactions
Time Frame: 15 years
|
% of patients with adverse drug reaction reported by investigators
|
15 years
|
Bleeding
Time Frame: 15 years
|
% of patients with bleeding during follow-up
|
15 years
|
Rescue treatment
Time Frame: 15 years
|
% of patients with any treatment added during the exposure of ongoing treatment
|
15 years
|
Adherence to ITP management guidelines.
Time Frame: 15 years
|
Percentage of patients who benefitted from the recommended examinations to detect secondary ITP and the percentage of patients who benefitted from the recommended first-line and second line treatments
|
15 years
|
Events
Time Frame: 15 years
|
% of patients with other events of interest like cancer, death, infection, thrombosis
|
15 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Moulis Guillaume, MD PhD, University Hopsital Toulouse
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (Estimated)
June 1, 2025
Study Completion (Estimated)
June 1, 2029
Study Registration Dates
First Submitted
July 2, 2016
First Submitted That Met QC Criteria
August 18, 2016
First Posted (Estimated)
August 24, 2016
Study Record Updates
Last Update Posted (Actual)
July 28, 2023
Last Update Submitted That Met QC Criteria
July 27, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Blood Coagulation Disorders
- Skin Manifestations
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Purpura, Thrombocytopenic
- Purpura
- Anemia
- Purpura, Thrombocytopenic, Idiopathic
- Thrombocytopenia
- Hemolysis
- Anemia, Hemolytic
- Anemia, Hemolytic, Autoimmune
Other Study ID Numbers
- RC31/12/0386
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune Thrombocytopenia
-
Institute of Hematology & Blood Diseases Hospital...Henan Cancer Hospital; Beijing Children's Hospital; Tianjin Medical University... and other collaboratorsRecruitingPrimary Immune Thrombocytopenia (ITP)China
-
argenxWithdrawnPrimary Immune Thrombocytopenia (ITP)
-
Novartis PharmaceuticalsRecruitingPrimary Immune Thrombocytopenia (ITP)China, United States, Spain, Singapore, Austria, Germany, Belgium, Italy, Japan, Czechia, Hong Kong, Hungary, Malaysia, Argentina, Bulgaria, Turkey, Vietnam, Australia, Thailand, Mexico, United Kingdom, France, Romania, Norway, India
-
University Children's Hospital BaselNovartis Pharmaceuticals; Stiftung zur Förderung medizinischer und biologischer... and other collaboratorsActive, not recruiting
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedAdult Patients | Immune Primary Thrombocytopenia | Splenectomy | TPO-mimeticsItaly
-
National Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationImmune Mediated Anemia | Immune Mediated Thrombocytopenia | Chronic GVHDUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingImmune Mediated Anemia | Immune Mediated Thrombocytopenia | Chronic GVHDUnited States
-
Changzhou No.2 People's HospitalRui Therapeutics Co., LtdNot yet recruitingThrombocytopenia Alloimmune
-
Nahda UniversityRecruiting
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingChronic Primary Immune Thrombocytopenia (ITP)China
Clinical Trials on no specific intervention
-
HaEmek Medical Center, IsraelCompleted
-
Sengkang General HospitalSingapore General Hospital; Duke-NUS Graduate Medical School; Lee Kong Chian...RecruitingObesity | Metabolic Syndrome | Sarcopenia | Chronic Inflammation | Sarcopenic ObesitySingapore
-
Armenian Cardiologists AssociationSanté Arménie French-Armenian Research CenterRecruitingST Elevation Myocardial InfarctionArmenia
-
Momentum DataCompleted
-
Shanghai University of Traditional Chinese MedicineUnknownCervical Spondylosis With MyelopathyChina
-
University Hospital, ToulouseCompleted
-
University Hospital Inselspital, BerneSwiss Heart Foundation; Cervical Artery Dissections and Ischemic Stroke Patients...UnknownStroke | Cerebrovascular Disorders | Vascular: Intracranial | Intimal DissectionJapan, Switzerland
-
Norwegian University of Science and TechnologyCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Recruiting
-
Peking Union Medical College HospitalRecruitingRectal NeoplasmsChina